Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


FDA's Clinical Hold on Investigational HCV Drug Continues
Regulus Therapeutic’s hepatitis C drug, RG-101, has been on clinical hold since mid-2016; FDA calls for additional data before hold is lifted.
HCV Combination Therapy Found Effective in European Patients
The retrospective study included a cohort of patients from six countries across Europe who were diagnosed with HCV and received daclatasvir during the Named Patient Program.
Cirrhosis Found Less Likely to Cause Liver Cancer Than Previously Thought
A new study finds that cancer incidence in individuals with cirrhosis is lower than originally believed—at most, about 4%.
Hepatitis C Genotype 4 Combination Therapy Found to Be Safe and Effective
According to the Belgian researchers, Sofosbuvir in combination with simeprevir with or without ribarivirn was found to be well-tolerated and efficacious.
Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.
Treatment Options for HCV Patients with Renal Impairment
A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.
Safety of New HCV Direct-Acting Antivirals Called into Question
A report warns that liver failure might be associated with nine new direct-acting antivirals (DAA).
Too Many Conflicts of Interest Found in HCV Management Guidelines
A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.